iBio, Inc. 8-K

What Happened
iBio, Inc. announced on April 8, 2026 that it received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, clearing the way to initiate a first‑in‑human Phase 1 clinical trial of IBIO‑600 in Australia. The company expects to dose first participants in the second quarter of 2026. The announcement was made via a press release filed as an 8‑K.

Key Details

• Announcement date: April 8, 2026; first dosing expected Q2 2026.
• Regulatory milestones: Clinical Trial Notification acknowledgement from Australia’s TGA and Human Research Ethics Committee ethics approval for IBIO‑600.
• Warrants impact: As a result of the announcement, Series G warrants (issued in the August 19, 2025 2025 Offering) will expire on May 12, 2026 (30 trading days after the public announcement).
• Outstanding Series G warrants: 27,945,000 warrants remain outstanding; if exercised before expiration they would convert into 27,945,000 shares of common stock and issue accompanying Series H warrants to purchase up to 27,945,000 additional shares (or pre‑funded warrants in lieu).

Why It Matters
This filing confirms a key development milestone for iBio’s IBIO‑600 program — regulatory clearance to begin human testing in Australia — which is an important clinical de‑risking event and could drive future value events (trial progress, data readouts, partnerships). Separately, the public announcement triggers a scheduled acceleration of the Series G warrant expiration (May 12, 2026). That creates a near‑term window in which holders may exercise, potentially resulting in meaningful share issuance and follow‑on Series H warrants; investors should monitor warrant exercises and potential dilution in the coming weeks.